1.483 hasil
Menampilkan 1–20 · 0,49 detik · RSS
JHEP Reports
Scopus
ISSN 2589-5559 · Elsevier · 1.483 artikel di indeks
-
Artikel Jurnal
Enhanced lysosomal glycogen breakdown is associated with liver tumorigenesis in glycogen storage disease type III
Background & Aims: Glycogen storage disease type III (GSDIII) is a rare metabolic disorder caused by mutations in the glycogen debranching enzyme (AGL), leading to hepatic glycogen accumulation, fibrosis and increased hepatocellular carcinoma (HCC) risk. This study investigates the metabolic…
-
Artikel Jurnal
Animal naming test at discharge is associated with hepatic encephalopathy after elective TIPS
Backgrounds & Aims: Overt hepatic encephalopathy (OHE) is the most feared complication after transjugular intrahepatic portosystemic shunt (TIPS) placement. We aimed to evaluate the usefulness of the animal naming test (ANT) in predicting the occurrence of OHE after elective TIPS placement…
-
Artikel Jurnal
Multidrug-resistant colonization in decompensated cirrhosis outside the ICU predicts infection and poor outcomes
Background & Aims: Infections caused by multidrug- (MDROs) or extensively drug- (XDROs) resistant organisms are an increasing global concern in cirrhosis. While MDRO colonization is a recognized risk factor for infection in critical care settings, evidence in ward-based patients with decompensated…
-
Artikel Jurnal
Carvedilol decreases hepatic vascular resistance by reducing fibrogenesis and reversing endothelial dysfunction in cirrhotic rats
Background & Aims: Cirrhosis increases hepatic vascular resistance (IHVR) by disrupting liver architecture due to fibrosis, and by elevating hepatic vascular tone due to hepatic endothelial dysfunction. IHVR increases portal pressure (PP), later aggravated by increased portal blood inflow…
-
Artikel Jurnal
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
Background & Aims: Durvalumab plus tremelimumab (STRIDE) has emerged as a first-line systemic treatment option for unresectable hepatocellular carcinoma (HCC). This international multicentre study aimed to evaluate the efficacy and tolerability of STRIDE or durvalumab monotherapy in routine…
-
Artikel Jurnal
Plasma exchange as potential treatment of severe immune checkpoint inhibitor-induced hepatitis
Background & Aims: Immune checkpoint inhibitors (ICIs) improve cancer survival but can cause severe immune-related hepatitis. Standard therapy with corticosteroids and second-line agents such as mycophenolate mofetil fails in some cases. Therapeutic plasma exchange (TPE) has been suggested as…
-
Artikel Jurnal
Proctocolectomy with permanent ileostomy is associated with improved transplant-free survival in patients with PSC
Background & Aims: The gut–liver axis is believed to be crucial in the pathogenesis of primary sclerosing cholangitis (PSC). However, the impact of colectomy on liver disease progression is unclear. Our study estimated the effect of colectomy on PSC progression with correction for time dependency…
-
Artikel Jurnal
Cumulative lipid exposure in young adulthood and risk of midlife MASLD
Background & Aims: The importance of maintaining optimal lipid levels across young adulthood in preventing metabolic dysfunction-associated steatotic liver disease (MASLD) is unclear. This study aimed to evaluate associations of lipid profiles through young adulthood with midlife MASLD risk and…
-
Artikel Jurnal
Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis
Background & Aims: Cirrhosis poses a significant healthcare burden, with decompensation and acute-on-chronic liver failure (ACLF) resulting in high morbidity and mortality. Reliable biomarkers of disease progression are urgently needed. Urokinase plasminogen activator receptor (uPAR) and its…
-
Artikel Jurnal
Longitudinal risk of cirrhosis by steatotic liver disease subtype among 1.5 million individuals in the US
Backgound & Aims: Steatotic liver disease (SLD), which includes metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic- and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD), is the leading cause of chronic liver disease in the US. However…
-
Artikel Jurnal
Factors associated with protection from MASLD in type 2 diabetes: A prospective study integrating longitudinal MRI/MRE and stable isotope tracing
Background & Aims: Type 2 diabetes is one of the strongest risk factors for the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). In this study, we aimed to identify factors associated with protection from MASLD in a prospective cohort of individuals…
-
Artikel Jurnal
Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab
Background & Aims: The membrane proteoglycan glypican-3 (GPC3) is expressed in ∼70%–80% of hepatocellular carcinomas (HCCs), and its soluble fragment is released into the circulation by protease cleavage. We investigated correlations between tumor and plasma GPC3 levels and their associations with…
-
Artikel Jurnal
Development and patterns of acute-on-chronic liver failure in patients with cirrhosis and acute kidney injury
Background & Aims: The prevalence and evolution of acute-on-chronic liver failure (ACLF), particularly extrarenal organ failures, in patients with cirrhosis and acute kidney injury (AKI) are not well characterized. This study investigated the development and progression of ACLF in patients with…
Menampilkan maksimal 50 halaman. Persempit pencarian dengan filter untuk hasil yang lebih spesifik.